SVP, Head of Strategy and Chief Business Officer, CytomX
Mr. Landau has over 20 years of biopharmaceutical experience in corporate development, corporate strategy, and new product strategy and planning. Most recently, Mr. Landau was senior vice president of corporate development, commercial, and new product strategy at Catalyst Biosciences, Inc. Additionally, he was a member of the Catalyst Biosciences executive management team responsible for partnering, license & acquisition, corporate strategy, pipeline and new product planning, alliance and project management. Prior to joining Catalyst, Mr. Landau held corporate development and global product and pipeline strategy roles of increasing responsibility at Threshold Pharmaceuticals and Onyx Pharmaceuticals (acquired by Amgen). Mr. Landau received his M.B.A. from Stanford Graduate School of Business and his B.S. with honors in biochemistry/biotechnology from Virginia Polytechnic Institute.